A$2.78 Artrya (AYA.AX) ASX pre-market 21 Mar 2026: AI diagnostics growth test

AYA.AX stock trades at A$2.78 in pre-market ASX trade on 21 Mar 2026 after a pullback from its year high of A$5.24. We see the move as the market re-pricing an AI healthcare developer that still reports negative earnings. Artrya Limited (AYA.AX) sells Salix, an AI tool for coronary artery disease detection. This update gives price context, analyst-style metrics, and a short-term forecast for active traders and AI-stock investors.

AYA.AX stock: Price snapshot and intraday context

Artrya (AYA.AX) opened pre-market at A$2.98 and sits at A$2.78 with the day range A$2.75–A$2.98. Volume is 816,706 shares versus an average of 532,447, so liquidity is healthy for this market cap.

Market cap is A$304,984,000 and shares outstanding are 113,800,000. Recent moves show YTD weakness of -47.14%, while the one-year return is +228.83%.

Business model and AI positioning

Artrya Limited (AYA.AX) sells Salix, a cloud AI that reads coronary CT angiography. The product targets radiology workflows and hospital networks where automation reduces reporting time.

Competitive context is evolving; peer comparisons appear on industry trackers and screens source. Market chatter and comparative analysis are captured in public feeds source.

Financials and valuation metrics for AYA.AX stock

Latest reported EPS is -0.17 and the trailing PE reads -15.76, reflecting negative earnings. Price to book is 3.91, book value per share is A$0.71, and cash per share is A$0.61.

Key ratios show a strong liquidity cushion with current ratio 37.11 and low debt to equity 0.01. Revenue per share is negligible at 0.00 and R&D intensity runs at 84.34% of revenue, consistent with a growth-stage AI medtech business.

Technical outlook and trading signals

Short-term momentum is weak; RSI is 37.34 and CCI reads -176.11, signalling oversold conditions. Moving averages show a 50-day average A$3.49 and 200-day average A$2.71, so price sits below the 50-day but above the 200-day.

Volatility measures include ATR A$0.26 and Bollinger Band middle A$3.18. Traders should watch support at A$2.75 and resistance near A$3.52 (upper BB).

Meyka AI rates AYA.AX with a score out of 100: grade, model and forecast

Meyka AI rates AYA.AX with a score out of 100. Meyka AI assigns a score 63.34 which maps to Grade B and a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a one-year price of A$7.41, a quarterly target of A$4.36, and a monthly target of A$3.05. Compared with the current price A$2.78, the one-year projection implies an upside of +166.57%. Forecasts are model-based projections and not guarantees.

We also highlight the internal valuation signals. Price to sales is extreme at 10,909.10, while EV to sales is 9,323.76, reflecting very low current revenue. Use the Meyka grade and forecasts as decision inputs only, not investment advice.

Risks and opportunities for investors

Key risks include continued negative earnings, slow hospital rollouts, and regulatory hurdles for AI diagnostics. Cash runway and funding cadence matter because revenue remains small.

Opportunities include larger commercial contracts, improved AI sensitivity that drives adoption, and international licensing. Risk-adjusted upside could be material if adoption scales and margins improve.

Final Thoughts

AYA.AX stock trades at A$2.78 in pre-market ASX trading on 21 Mar 2026, with clear upside scenarios but visible execution risk. Our analysis weighs heavy R&D spend and negative EPS against robust cash per share and an AI product that addresses a defined clinical need. Meyka AI’s forecast model projects A$7.41 in one year, implying a +166.57% upside from today. Conservative short-term targets include A$3.50 and a base target A$4.36 tied to quarterly estimates. Traders should combine the technical signals—RSI 37.34, 50-day average A$3.49—with ongoing contract news. Meyka AI is the AI-powered market analysis platform used for the grade and forecast. Forecasts are model outputs and not guarantees. For risk-managed exposure, consider position sizing and a clear trigger for reevaluation, such as a commercial revenue update or a material contract announcement.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.